An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011

Health Affairs

Volumn 32, Issue 8, 2013, Pages 1433-1439

  Lanthier, Michael ^a   Miller, Kathleen L ^a,b   Nardinelli, Clark ^a   Woodcock, Janet ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG INDUSTRY; UNITED STATES;

BIOTECHNOLOGY; BUSINESS OF HEALTH; HEALTH ECONOMICS; PHARMACEUTICALS; PUBLIC HEALTH;

DIFFUSION OF INNOVATION; DRUG APPROVAL; DRUG DESIGN; DRUG DISCOVERY; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; FORECASTING; HUMANS; UNITED STATES;

EID: 84884271849     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2012.0541     Document Type: Article

References (23)

1. Lichtenberg FR. Pharmaceutical innovation, mortality reduction, and economic growth. Cambridge (MA): National Bureau of Economic Research; 1998. (Working Paper No. 6569).
2. Grabowski HG, Wang YR. The quantity and quality of worldwide new drug introductions, 1982-2003. Health Aff(Millwood). 2006;25(2): 452-60.
3. Light DW. Global drug discovery: Europe is ahead. Health Aff(Millwood). 2009;28(5):w969-77. DOI: 10.1377/hlthaff.28.5.w969.
4. Kola I. The state of innovation in drug development. Clin Pharmacol Ther. 2008;83(2):227-30.
5. DiMasi JA. New drug innovation and pharmaceutical industry structure: trends in the output of pharmaceutical firms. Drug Inf J. 2000; 34(4):1169-94.
6. Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin Pharmacol Ther. 2011;89(2):183-8.
7. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9(3):203-14.
8. Cockburn IM. Is the pharmaceutical industry in a productivity crisis? Chapter 1 in: Jaffe AB, Lerner J, Stern S, editors. Innovation policy and the economy. Volume 7. Cambridge (MA): MIT Press; 2007. p. 1-32.
9. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8(12):959-68.
10. To access the Appendix, click on the Appendix link in the box to the right of the article online.
11. US sales data for the top twenty-five pharmacuetical companies are from three IMS Health publications: for 1980-86, "US Pharmaceutical Market: Drug Store and Hospital Purchases (January-December)"; for 1997-2000, "Retail Perspective and Provider Perspective (January- December)"; and for 2001-10, "National Sales Perspectives: Retail and Non-Retail Combined Report (January-December)."
12. Drug facts and comparisons [proprietary online database]. St. Louis (MO): Wolters Kluwer Health; 2007.
13. Pharmaprojects [proprietary online database]. Richmond (UK): PJB Publications; 2007.
14. Wertheimer AI, Levy R, O'Connor TW. Too many drugs? The clinical and economic value of incremental innovations. Chapter 4 in: Farquhar I, Sorkin A, Summers K, editors. Research in human capital and development: investing in health: the social and economic benefits of health care innovation. Volume 14. Greenwich (CT): JAI Press; 2001. p. 77-118.
15. Food and Drug Administration. White paper: Prescription Drug User Fee Act (PDUFA): adding resources and improving performance in FDA review of new drug applications [Internet]. Silver Spring (MD): FDA; 2005 [last updated 2010 May 3; cited 2013 Jun 27]. Available from: http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm119253.htm
16. Cockburn IM. The changing structure of the pharmaceutical industry. Health Aff(Millwood). 2004;23(1): 10-22.
17. Food and Drug Administration. Innovation or stagnation: challenge and opportunity on the critical path to new medical products. Silver Spring (MD): FDA; 2004.
18. DiMasi JA, Paquette C. The economics of follow-on drug research and development. Pharmacoeconomics. 2004;22(2):1-14.
19. Murray MD, DeardorffFW. Does managed care fuel pharmaceutical industry growth? Pharmacoeconomics. 1998;14(4):341-8.
20. Gassmann O, Reepmeyer G, Von Zedtwitz M. Leading pharmaceutical innovation: trends and drivers for growth in the pharmaceutical industry. Berlin: Springer; 2008.
21. Pammolli F, Riccaboni M. Market structure and drug innovation. Health Aff(Millwood). 2004;23(1): 48-50.
22. Cohen FJ. Macro trends in pharmaceutical innovation. Nat Rev Drug Discov. 2005;4(1):78-84.
23. President's Council of Advisors on Science and Technology. Report to the president on propelling innovation in drug discovery, development, and evaluation. Washington (DC): PCAST; 2012.